MELTZER LESLIE
Insider CIK 2084030 · APLS Chief Research and Development
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| APLS Apellis Pharmaceuticals, I | D To issuer deriv | 2026-05-14 | 2026-05-14 | 92,592 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | D To issuer | 2026-05-14 | 2026-05-14 | 45,220 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award | 2026-05-14 | 2026-05-14 | 45,220 | — | $0 | 45,220 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | D To issuer | 2026-05-14 | 2026-05-14 | 45,220 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award | 2026-05-14 | 2026-05-14 | 22,610 | — | $0 | 22,610 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | U Tender | 2026-05-14 | 2026-05-14 | 107,024 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | D To issuer | 2026-05-14 | 2026-05-14 | 61,804 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | D To issuer | 2026-05-14 | 2026-05-14 | 22,610 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award | 2026-01-28 | 2026-01-30 | 45,220 | — | $0 | 107,024 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award deriv | 2025-08-26 | 2025-09-02 | 92,592 | — | $0 | 92,592 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award | 2025-08-26 | 2025-09-02 | 61,804 | — | $0 | 61,804 | SEC↗ |